Letter | Published:

Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities


The breast and ovarian cancer susceptibility gene, BRCA1, has been cloned and shown to encode a zinc-finger protein of unknown function1. Mutations in BRCA1 account for at least 80% of families with both breast and ovarian cancer, as well as some non-familial sporadic ovarian cancers2,3. The loss of wild-type BRCA1 in tumours of individuals carrying one nonfunctional BRCA1 allele suggests that BRCA1 encodes a tumour suppressor4–6 that may inhibit the proliferation of mammary epithelial cells7. To examine the role of BRCA1 in normal tissue growth and differentiation, and to generate a potential model for the cancer susceptibility associated with loss of BRCA1 function, we have created a mouse line carrying a mutation in one Brcal allele. Analysis of mice homozygous for the mutant allele indicate that Brcal is critical for normal development, as these mice died in utero between 10 and 13 days of gestation (E10–E13). Abnormalities in Brcal -deficient embryos were most evident in the neural tube, with 40% of the embryos presenting with varying degrees of spina bifida and anencephaly. In addition, the neuroepithelium in Brca 1-deficient embryos appeared disorganized, with signs of both rapid proliferation and excessive cell death.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Miki, Y. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66–71 (1994).

  2. 2

    Easton, D.F. et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Science 52, 678–701 (1993).

  3. 3

    Merajver, S.D. et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet. 9, 439–443 (1995).

  4. 4

    Smith, H.S. et al. Molecular aspects of early stages of breast cancer progression. J. Cell. Biochem. 176, 144–152 (1993).

  5. 5

    Kelsell, DP., Black, D.M., Bishop, D.T .& Spurr, N.K. Genetic analysis of the BRCA1 region in a large breast/ovarian family: refinement of the minimal region containing BRCA1. Hum. Mol. Genet. 2, 1823–1828 (1993).

  6. 6

    Neuhausen, S. & Marshall, C.J. Loss of heterozygosity in familial tumours from three BRCA1 -linked kindreds. Cancer Res. 54, 6069–6072 (1994).

  7. 7

    Thompson, M.E., Jensen, R.A., Obermiller, P.S., Page, D.L. & Holt, J.T. Decreased expression of BRCAl accelerates growth and is often present during sporadic breast cancer progression. Nature Genet. 9, 444–450 (1995).

  8. 8

    Marquis, S.T. et al. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nature Genet. 11, 17–26 (1995).

  9. 9

    Donehower, L.A. et al. Mice deficient for p53 are developmentaly normal but susceptible to spontaneous tumours. Nature 356, 215–221 (1992).

  10. 10

    Jacks, T et al. Effects of an Rb mutation in the mouse. Nature 359, 295–300 (1992).

  11. 11

    Clarke, A.R. et al. Requirement for a functional Rb-1 gene in murine development. Nature 359, 328–330 (1992).

  12. 12

    Sulik, K.K. & Sadler, T.W. Postulated mechanisms underlying the development of neural tube defects. Ann. N.Y. Acad. Sci. 678, 8–21 (1993).

  13. 13

    Boyd, M., Harris, F., McFarlane, R., Davidson, H.R. & Black, D.M. A human BRCA1 gene knockout. Nature 375, 541–542 (1995).

  14. 14

    Dombrowicz, D., Flamand, V., Brigman, K.K., Koller, B.H. & Kinet, J.R. Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor alpha chain gene. Cell 75, 969–976 (1993).

  15. 15

    Shattuck-Eidens, D. . et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening. JAMA 273, 535–541 (1995).

  16. 16

    Reid, L.H., Gregg, R.G., Smithies, O. & Koller, B.H. Regulatory elements in the introns of the hprt gene are necessary for its expresion in embryonic stem cells. Proc. Natl. Acad. Sci. USA 87, 4299–4303 (1990).

  17. 17

    Hooper, M., Hardy, K., Handyside, A., Hunter, S. & Monk, M. HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature 326, 292–295 (1987).

  18. 18

    Mohn, A.R. & Koller, B.H. Genetic manipulation of embryonic stem cells. In DNA Cloning — Mammalian Systems: A Practical Approach, (ed. I. Hall) 142–184 (Oxford Univ. Press, Oxford, 1995).

  19. 19

    Miller, S.A., Dykes, D.D. & Polesky, H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl. Acids Res. 16, 1215 (1988).

  20. 20

    Abel, K.J. et al. Mouse Brcal: localization, sequence analysis and identification of evolutionary conserved domains. Hum. Mol. Genet. 4, 2265–2273 (1995).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading